Ryan Deschner
Stock Analyst at Raymond James
(4.70)
# 800
Out of 5,162 analysts
77
Total ratings
58.8%
Success rate
28.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACOG Alpha Cognition | Reiterated: Buy | $20 → $21 | $8.85 | +137.29% | 2 | Nov 12, 2026 | |
| LQDA Liquidia | Reiterated: Buy | $53 → $77 | $56.63 | +35.97% | 15 | Nov 11, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $230 | $145.77 | +57.78% | 4 | Nov 6, 2026 | |
| SPRY ARS Pharmaceuticals | Reiterated: Buy | $17 | $3.36 | +405.95% | 12 | Nov 5, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | n/a | $26.75 | - | 8 | Sep 15, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $27 → $40 | $13.72 | +191.55% | 6 | Aug 7, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $10 | $0.9461 | +956.97% | 5 | Jul 8, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $14 → $10 | $1.05 | +852.38% | 2 | Jun 26, 2026 | |
| QUIT Achieve Life Sciences | Initiated Coverage: Buy | $20 | $5.87 | +240.72% | 1 | Jun 26, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $25.84 | - | 2 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $84.83 | - | 5 | Jun 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $21 | $13.34 | +57.42% | 1 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.09 | +725.69% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $110 → $165 | $95.51 | +72.76% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $12.19 | +88.68% | 2 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $12 | $3.06 | n/a | 4 | Aug 5, 2025 |
Alpha Cognition
Nov 12, 2026
Reiterated: Buy
Price Target: $20 → $21
Current: $8.85
Upside: +137.29%
Liquidia
Nov 11, 2026
Reiterated: Buy
Price Target: $53 → $77
Current: $56.63
Upside: +35.97%
Palvella Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $230
Current: $145.77
Upside: +57.78%
ARS Pharmaceuticals
Nov 5, 2026
Reiterated: Buy
Price Target: $17
Current: $3.36
Upside: +405.95%
Vera Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $26.75
Upside: -
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $27 → $40
Current: $13.72
Upside: +191.55%
Tvardi Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $10
Current: $0.9461
Upside: +956.97%
ProQR Therapeutics
Jun 26, 2026
Reiterated: Buy
Price Target: $14 → $10
Current: $1.05
Upside: +852.38%
Achieve Life Sciences
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $5.87
Upside: +240.72%
Viking Therapeutics
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.84
Upside: -
Jun 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $84.83
Upside: -
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $13.34
Upside: +57.42%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.09
Upside: +725.69%
May 7, 2026
Reiterated: Buy
Price Target: $110 → $165
Current: $95.51
Upside: +72.76%
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $12.19
Upside: +88.68%
Aug 5, 2025
Reiterated: Buy
Price Target: $11 → $12
Current: $3.06
Upside: n/a